Trial reportBMC medicine2018
Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia.
Trial report in BMC medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02344498 (Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and individual-patient-data meta-analysis of non-invasive fibrosis markers for chronic hepatitis B in Africa.Nature communications · 2023Pooled it
- A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection.Alimentary pharmacology & therapeutics · 2026Article
- Global disparities in liver cancer burden: an epidemiological and socioeconomic analysis using GBD 1990-2021 data.Discover oncology · 2026Article
- Hepatitis B treatment response and factors associated with HBV treatment success: A population-based study in Rwanda.Hepatology communications · 2026Article
- Decentralization of hepatitis B care in sub-Saharan Africa: study protocol for a prospective cohort assessing three models of care in rural Ethiopia.BMC health services research · 2025Observational
- Intra-familial transmission of Hepatitis B virus in a peri-urban community from the Democratic Republic of the Congo.Tropical medicine and health · 2025Article
- Predictors of Medication Non-Adherence Among Hepatitis B Patients in South Sudan: A Health-Facility-Based Cross-Sectional Study.Patient preference and adherence · 2025Article
- Machine-learning methodologies to predict disease progression in chronic hepatitis B in Africa.Hepatology communications · 2024Article
- Chronic hepatitis B virus infection in Eastern Ethiopia: Clinical characteristics and determinants of cirrhosis.World journal of hepatology · 2024Article
- Clinical, Gender, Socioeconomic Characteristics and Outcomes of Individuals Receiving Hepatitis B Treatment in Ethiopia: 18-Month Follow-Up.The American journal of tropical medicine and hygiene · 2023Article
- Article
- Renal Safety of Long-term Tenofovir Disoproxil Fumarate Treatment in Patients With Chronic Hepatitis B.Open forum infectious diseases · 2023Article
- Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries.JHEP reports : innovation in hepatology · 2023Review
- A new approach to prevent, diagnose, and treat hepatitis B in Africa.BMC global and public health · 2023Review
- Hepatitis B Vaccination Impact and the Unmet Need for Antiviral Treatment in Blantyre, Malawi.The Journal of infectious diseases · 2022Article
- Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B.The lancet. HIV · 2022Review
- Long-term effect of chronic hepatitis B on mortality in HIV-infected persons in a differential HBV transmission setting.BMC infectious diseases · 2022Article
- Chronic Hepatitis B Infection with Low Level Viremia Correlates with the Progression of the Liver Disease.Journal of clinical and translational hepatology · 2021Article
- Hepatocellular Carcinoma in Sub-Saharan Africa.JCO global oncology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe World Health Organization has set an ambitious goal of eliminating viral hepatitis as a major public health threat by 2030. However, in sub-Saharan Africa, antiviral treatment of chronic hepatitis B (CHB) is virtually unavailable. Herein, we present the 1-year results of a pilot CHB treatment program in Ethiopia.
methodsAt a public hospital in Addis Ababa, CHB patients were treated with tenofovir disoproxil fumarate based on simplified eligibility criteria. Baseline assessment included liver function tests, viral markers, and transient elastography (Fibroscan). Changes in laboratory markers were analyzed using Wilcoxon signed-rank tests. Adherence to therapy was measured by pharmacy refill data.
resultsOut of 1303 patients, 328 (25.2%) fulfilled the treatment criteria and 254 (19.5%) had started tenofovir disoproxil fumarate therapy prior to September 1, 2016. Of the patients who started therapy, 30 (11.8%) died within the first year of follow-up (28 of whom had decompensated cirrhosis), 9 (3.5%) self-stopped treatment, 7 (2.8%) were lost to follow-up, and 4 (1.6%) were transferred out. In patients who completed 12 months of treatment, the median Fibroscan value declined from 12.8 to 10.4 kPa (p < 0.001), 172 of 202 (85.1%) patients with available pharmacy refill data had taken ≥ 95% of their tablets, and 161 of 189 (85.2%) patients with viral load results had suppressed viremia. Virologic failure (≥ 69 IU/mL) at 12 months was associated with high baseline HBV viral load (> 1,000,000 IU/mL; adjusted OR 2.41; 95% CI 1.04-5.55) and suboptimal adherence (< 95%; adjusted OR 3.43, 95% CI 1.33-8.88).
conclusionsThis pilot program demonstrated that antiviral therapy of CHB can be realized in Ethiopia with good clinical and virologic response. Early mortality was high in patients with decompensated cirrhosis, underscoring the need for earlier detection of hepatitis B virus infection and timely initiation of treatment, prior to the development of irreversible complications, in sub-Saharan Africa.
trial registrationNCT02344498 (ClinicalTrials.gov identifier). Registered 16 January 2015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.